SWM
NBSE

SeaCrest Wealth Management’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

SeaCrest Wealth Management’s Portfolio NBSE Stock Details NBSE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-6
Closed – – 1944
2019
Q1 		$0 Hold
6
– – ﹤0.01% 2248
2018
Q4 		$0 Hold
6
– – ﹤0.01% 2324
2018
Q3 		$0 Hold
6
– – ﹤0.01% 2348
2018
Q2 		$0 Hold
6
– – ﹤0.01% 2307
2018
Q1 		$1K Hold
6
– – ﹤0.01% 2147
2017
Q4 		$5K Buy
+6
New +$2.32K ﹤0.01% 1823

Other funds holding NBSE

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MIG
Mariner Investment Group Harrison, New York $346M AUM 25.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
LTFS
Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return
SSB
Sandy Spring Bank Olney, Maryland $2.38B AUM 8.14% 1-Year Est. Return
CLOS
Compagnie Lombard Odier SCmA 1204 Geneva, Switzerland $8.13B AUM 26.03% 1-Year Est. Return

SeaCrest Wealth Management's NBSE Position: Q2 2019 in Review

SeaCrest Wealth Management sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q2 2019, closing a stake of 6 shares.

SeaCrest Wealth Management first reported a position in NBSE in Q4 2017 and held it in 6 quarters. The position peaked at $5K in Q4 2017. 13 funds tracked by Wall St. Rank hold NBSE as of Q2 2019.

  • SeaCrest Wealth Management reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q2 2019 after selling out during the quarter.
  • SeaCrest Wealth Management sold 6 NeuBase Therapeutics, Inc. Common Stock shares in Q2 2019.
  • SeaCrest Wealth Management first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q4 2017 and held it in 6 quarters.
  • SeaCrest Wealth Management's NeuBase Therapeutics, Inc. Common Stock position peaked at $5K in Q4 2017.
  • 13 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q2 2019.

Based on SeaCrest Wealth Management's 13F filing for Q2 2019, filed 19 Jul 2019.